MedTrace Logo

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality

NCT07769164 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2026-08-19

No results posted yet for this study

Summary

This double-blind, randomized, placebo-controlled study will assess the safety and effects of different combinations of CBN, CBG, and THC, with and without CBD and melatonin, for enhancing sleep quality, other factors related to sleep, daytime fatigue, and mood symptoms related to sleep (i.e., depression, anxiety, irritability, and perceived stress).

Conditions

  • Sleep Disturbance
  • Sleep Quality

Interventions

DIETARY_SUPPLEMENT

2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin

Fast Asleep Gummy

DIETARY_SUPPLEMENT

10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD

Stay Asleep Gummy

DIETARY_SUPPLEMENT

10 mg THC + 20 mg CBN + 5 mg CBG

Stay Asleep-Revision

DIETARY_SUPPLEMENT

Stay Asleep Placebo

Same inactive ingredients as study IP

DIETARY_SUPPLEMENT

Fast Asleep Placebo

Same inactive ingredients as study IP

Sponsors & Collaborators

  • Wana Brands

    collaborator UNKNOWN

  • Cannabis Science Innovations, LLC

    lead INDUSTRY

Principal Investigators

  • Marcel O Bonn-Miller, PhD · Cannabis Science Innovations, LLC

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07769164 on ClinicalTrials.gov